21103-33-3

Basic information

• Product Name: 4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-BUTYLAMINE
• Synonyms: 4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-BUTYLAMINE;1-(4-aMino-1-butyl)-4-(2-Methoxyphenyl)piperazine;1-(4-Aminobutyl)-4-(2-methoxyphenyl)piperazine;4-[4-(2-Methoxyphenyl)-1-piperazinyl]butylamine
• CAS NO: 21103-33-3
• Molecular Formula: C₁₅H₂₅N₃O
• Molecular Weight: 263.3785
• Mol File: 21103-33-3.mol

Chemical Properties

• Boiling Point: 405.501°C at 760 mmHg
• Flash Point: 199.04°C
• Appearance: /
• Density: 1.049g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-BUTYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-BUTYLAMINE(21103-33-3)
• EPA Substance Registry System: 4-[4-(2-METHOXY-PHENYL)-PIPERAZIN-1-YL]-BUTYLAMINE(21103-33-3)

Safety Data

• Hazard Codes: C
• Statements: 34-52
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 2735PSN1 8 / PGII
• Hazardous Substances Data: 21103-33-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H25N3O/c1-19-15-7-3-2-6-14(15)18-12-10-17(11-13-18)9-5-4-8-16/h2-3,6-7H,4-5,8-13,16H2,1H3

Upstream product

• 102392-05-2 2-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-isoindole-1,3-dione 
• 5394-18-3 2-(4-bromobutyl)isoindoline-1,3-dione 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 1221408-65-6 4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-1-amine hydrochloride 
• 25024-99-1 4‐[4‐(2‐methoxyphenyl)piperazin‐1‐yl]butannitrile 
• 5464-78-8 1-(2-methoxyphenyl)piperazine hydrochloride 

Downstream Products

• 134390-72-0 4-[4-(1-adamantanecarboxamido)butyl]-1-(2-methoxyphenyl)piperazine 
• 115338-28-8 N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide 
• 134390-68-4 1-(2-methoxyphenyl)-4-<4-(4-phenytlbutyramido)butyl>piperazine 
• 114222-46-7 4,4a,5,5a,6,6a-hexahydro-2-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]4,6-ethenocycloprop[f]isoindole-1,3(2H,3AH)-dione 
• 134390-76-4 4-<4-<4-(benzyloxy)benzamido>butyl>-1-(methoxyphenyl)piperazine 
• 130475-74-0 3-<4-<4-(2-methoxyphenyl)piperazin-1-yl>butyl>thieno<3,4-d>pyrimidine-2,4-dione 

Relevant articles and documents

Preparation, characterization, and screening of a high affinity organometallic probe for α-adrenergic receptors

Figure Presented. An organometallic rhenium complex having high and selective affinity for α-adrenergic receptors is reported. A series of methoxyphenylpiperazinecarborane ligands complexed to the [Re(CO) 3]+ core were prepared and t

Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases

Owing to their multifunctional pharmacological profiles (including dual 5-HT1A/5-HT7 action), arylpiperazine derivatives are widely used for treating central nervous system diseases including the depression or neuropathic pain. Herein we describe the design, synthesis and evaluation of biological activity of novel 5-HT7 ligands derived of 2,4,6-triamino-1,3,5-triazine. The studied compounds showed affinity and high selectively towards 5-HT7 receptor with the two most active compounds 34 (Ki = 61 nM), 22 (Ki = 109 nM) showing good metabolic stability and moderate affinity to CYP3A4 isoenzyme. Compound 22 had high hepatotoxicity at a concentration below 50 μM, while compound 34 showed low hepatotoxicity even at a concentration above 50 μM.

Synthesis, in silico, and in vitro studies of novel dopamine D2 and D3 receptor ligands

Dopamine is an important neurotransmitter in the human brain and its altered concentrations can lead to various neurological diseases. We studied the binding of novel compounds at the dopamine D2 (D2R) and D3 (D3/sub

Compound with dopamine D3 receptor adjusting activity, and applications thereof

The invention relates to a compound with dopamine D3 receptor adjusting activity, and applications thereof, and more specifically discloses dopamine receptor D3R as a novel target of post-traumatic stress disorder (PTSD) in prevention, treatment/or auxiliary treatment of PTSD, and screening of anti-PTSD medicines, and relates to applications of a compound with dopamine receptor D3R adjusting activity in preparation of medicines used for preventing, treatment and/or auxiliary treatment of PTSD.

Benzyl Phenylsemicarbazides: A Chemistry-Driven Approach Leading to G Protein-Biased Dopamine D4 Receptor Agonists with High Subtype Selectivity

Many subtype-selective dopamine receptor ligands developed for the D2-D4 family incorporate a 1-arylpiperazine-derived primary recognition motif, which is connected to a lipophilic moiety occupying an extended binding pocket (EBP) of the receptor via an aliphatic linker of variable lengths. The evaluation of a novel group of dopamine receptor ligands now showed that highly subtype-selective ligands [up to Ki(D4.4) = 0.25 nM, D2L/D4.4 = 320, D3/D4.4 = 710 for APH199 (17)] can be obtained by choosing a relatively large and conformationally flexible 1-benzyl-1-phenylsemicarbazide substructure to fill the EBP. The novel chemotype APH199 (17) was found to act as a full agonist at the D4 receptor showing significant bias toward G protein activation over β-arrestin recruitment in comparison to quinpirole.

Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligands

As part of our on-going effort to explore the role of dopamine receptors in drug addiction and identify potential novel therapies for this condition, we have a identified a series of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamide D3 ligands. Members of this class are highly selective for D3 versus D2, and we have identified two compounds (13g and 13r) whose rat in vivo IV pharmacokinetic properties that indicate that they are suitable for assessment in in vivo efficacy models of substance use disorders.

Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase

We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R). Both targets are relevant for tackling several types of addiction (most notably nicotine addiction) and other compulsive behaviors. Here, we report an SAR exploration of a series of biphenyl-N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, a novel class of molecules that had shown promising activities at the FAAH-D3R target combination in preliminary studies. We have rationalized the structural features conducive to activities at the main targets and investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1. To understand the unexpected affinity for the CB1 receptor, we devised a 3D-QSAR model, which we then prospectively validated. Compound 33 was selected for PK studies because it displayed balanced affinities for the main targets and clear selectivity over the two off-targets. 33 has good stability and oral bioavailability and can cross the blood-brain barrier.

Photochromic Dopamine Receptor Ligands Based on Dithienylethenes and Fulgides

We describe the incorporation of the well-investigated class of photochromic dithienylethenes (DTEs) and fulgides into known dopamine receptor ligands such as 1,4-disubstituted aromatic and hydroxybenzoxazinone piperazines as well as aminoindanes. Subtype

Synthesis, preclinical evaluation and molecular modelling of macrocyclic appended 1-(2-methoxyphenyl)piperazine for 5-HT1A neuroreceptor imaging

5-HT1A receptors are known to be implicit in a number of neuropsychiatric fluctuations related to mood and anxiety. Their visualization in the human brain using PET, SPECT or MRI is of great importance in the management and treatment of neurolo

Visible-Light-Mediated Synthesis of Amides from Aldehydes and Amines via in Situ Acid Chloride Formation

An efficient visible-light photocatalysis-based one-pot amide synthesis method was developed; visible-light irradiation of a mixture of an aldehyde, tert-butyl hydrogen peroxide, and N-chlorosuccinimide using a Ru(bpy)3Cl2 photocatalyst afforded an acid chloride, which subsequently reacted with amine to yield the corresponding amide. The reaction was used to synthesize moclobemide and a D3 receptor intermediate.